MetaVia Inc. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $5.3 million, or $0.90 per share, compared to a $4.0 million loss in the prior year period. Research and development expenses increased to approximately $3.5 million from $2.3 million, driven by higher direct costs for DA-1726 product development. The company holds $12.6 million in cash and cash equivalents as of June 30, 2026, which management expects will be adequate to fund operations through 2026. Clinically, MetaVia announced that all active patients in the Phase 1 Part 3 study of DA-1726 successfully reached the highest planned dose levels of 48 mg and 64 mg. Topline data from this 16-week titration study is expected in the fourth quarter of 2026, while the company continues to advance vanoglipel (DA-1241) for MASH through preclinical combination studies and planned FDA meetings.

MetaVia Inc. announced that all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment, have completed dose titration and are receiving target doses of 48 mg and 64 mg. Topline data from the trial is expected to be released in the fourth quarter of 2026. MetaVia Inc. is a biotechnology company developing clinical-stage drug candidates for metabolic diseases.

MetaVia Inc. filed a prospectus supplement on July 2, 2026, to offer and sell up to $4,000,000 of common stock under an existing At The Market offering agreement with Ladenburg Thalmann & Co. Inc. MetaVia Inc. is a technology company providing software solutions.

At the 2026 virtual annual meeting of stockholders, MetaVia Inc. stockholders approved a reverse stock split in a ratio range of 1-for-5 to 1-for-22. Additionally, stockholders also approved an amendment to the 2022 Equity Incentive Plan to increase the share count by 200,000 shares.

MetaVia Inc. presented late-breaking data from its obesity and metabolic disease portfolio at the ADA 2026 Scientific Sessions. The Phase 1 results for DA-1726 showed a 9.1% body weight reduction at Day 54, while preclinical studies for vanoglipel demonstrated significant weight loss and hepatoprotective effects in combination treatments.